RISK WARNING: Your capital is at risk. The risks include: the lack of liquidity in this market in terms of being able to sell shares; the loss of the value of investment; and dilution of shareholding. When you invest any loss in value will not be covered by the Financial Services Compensation Scheme. Please read FULL risk warning.
Bodytrak, a physiological monitoring solution that delivers real time analytics via a SaaS platform.
Investment closes only once the total pledged amount passes the minimum of £1,000,000
A pledge is not a commitment. You will be asked to confirm in the next section.
This company has not shared it's twitter feed.
Data is sent to the platform via patented sensor technology, in the form of a non-invasive earpiece. The product accesses the ear, the only body site from which all vital signs can be measured, including core body temperature (CBT), heart rate, VO2 and motion detection (which acts as a fall detection/man-down alert). These core parameters are monitored continuously, and real-time data is sent to the Bodytrak cloud-based analytics platform.
The platform utilises machine learning to provide health and well being reports, alerting a supervisor or commander if early intervention is required to prevent injury and illness.
Bodytrak has been validation tested by Loughborough University, Portsmouth University and GlaxoSmithKline. They have also planned over forty trials of which some have already been completed. Moreover, Bodytrak have also secured a £200k contract from the Ministry of Defence and sold their first prototypes to Formula 1 and defence organisations.